NuCana plc (NASDAQ:NCNA) Short Interest Up 73.9% in December

NuCana plc (NASDAQ:NCNA) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 144,300 shares, a growth of 73.9% from the December 15th total of 83,000 shares. Based on an average daily trading volume, of 171,900 shares, the short-interest ratio is presently 0.8 days. Currently, 3.9% of the company’s stock are sold short.

NuCana Stock Up 4.8 %

Shares of NASDAQ NCNA traded up $0.05 during trading hours on Wednesday, hitting $1.09. 22,955 shares of the stock were exchanged, compared to its average volume of 132,543. The company has a market cap of $2.88 million, a PE ratio of -0.10 and a beta of 0.97. NuCana has a 12 month low of $0.96 and a 12 month high of $19.41. The firm has a fifty day moving average price of $1.30 and a 200-day moving average price of $2.60.

Hedge Funds Weigh In On NuCana

A hedge fund recently bought a new stake in NuCana stock. Glass Jacobson Investment Advisors llc purchased a new position in NuCana plc (NASDAQ:NCNA) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 15,000 shares of the company’s stock, valued at approximately $38,000. Glass Jacobson Investment Advisors llc owned about 0.57% of NuCana at the end of the most recent quarter. Institutional investors and hedge funds own 44.00% of the company’s stock.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.